Evaluation of diagnostic and prognostic candidate biomarkers in drug-induced liver injury vs. other forms of acute liver damage

PUBLICATIONSLeave a comment

Citation: Br J Clin Pharmacol. 2023; 89:2497–2507 DOI:10.1111/bcp.15724 Abstract Aims Detection and characterization of idiosyncratic drug-induced liver injury (DILI) currently rely on standard liver tests, which are suboptimal in terms of specificity, sensitivity and prognosis. Therefore, DILI diagnosis can be delayed, with important consequences for the patient. In this study, we aimed to evaluate the…

MAGPIX and FLEXMAP 3D Luminex platforms for direct detection of miR-122-5p through dynamic chemical labelling

PUBLICATIONSLeave a comment

Citation: Analyst, 2023, Advance Article DOI: 10.1039/D3AN01250F Abstract MicroRNAs (miRs) have emerged as promising biomarkers for diagnosing and predicting the prognosis of liver injury. This study aimed to compare the performance of two Luminex platforms, MAGPIX and FLEXMAP 3D, utilizing the innovative Dynamic Chemical Labelling (DCL) technology for direct detection and analysis of miR-122-5p in…

Diagnosing Alzheimer’s Disease – Project granted with more than €1.3 million in aid under the Colaboración Público Privada Program

PRESS RELEASESLeave a comment

Destina Genomica SL is part of a consortium formed by the Foundation for Biomedical Research of the Ramón y Cajal University Hospital (Madrid, Spain), the Advanced Photonic and Biofunctional Materials Group of the UAM (Autonomous University of Madrid, Spain) and led by the Spanish company Mecwins SA (Madrid) that has just received a grant of…

OPEN A NEW WINDOW ON THE WORLD OF CIRCULATING MICRORNA BIOMARKERS BY MERGING CHEMIRNATM TECH WITH AVAC ANALYZER

PRESS RELEASESLeave a comment

We are excited to announce a new project that changes the way we analyze miRNA-122. This small non-coding RNA is known as a biomarker for liver injury. With the support of the 2022 ICEX-Invest in Spain’s funding program, we are implementing the unique PCR-Free testing of miRNA-122 using DESTINA’s ChemiRNATM Tech reagents merged with AVAC…

DESTINA Genomics and Mecwins join forces to develop more reliable diagnostic tests

PRESS RELEASESLeave a comment

DESTINA Genomics and Mecwins join forces to develop more reliable diagnostic tests   Both biotechnology firms have signed a cross-licensing agreement to share technology to develop RNA quantification tests directly from biological samples. Initial tests will focus both on RNA biomarkers for drug-induced hepatotoxicity, nephrotoxicity and cardiotoxicity, and on therapeutic RNAs.  Thanks to the combination…

DESTINA featuring at Virtual Symposium On Ultrasensitive Immunoassays: The Power of Single Molecule Counting (SMC™) Technology organised by MilliporeSigma

EVENTSLeave a comment

On Wednesday 31 March 2021, DESTINA’s Juan Jose Diaz-Mochon will present the First Single Molecule Counting (SMC™) Application with miRNAs by a PCR Free Method. You can register here to watch the presentation https://lnkd.in/eiMknq9 The high specificity of DESTINA technologies has been implemented within the ultrasensitive SMC™ to yield the platform’s first molecular assays. During his presentation, Juan…

Amplification-free profiling of microRNA-122 biomarker in DILI patient serums, using the Luminex MAGPIX system

PUBLICATIONS

Citation: Talanta, 2020, doi: 10.1016/j.talanta.2020.121265 Abstract Dynamic chemical labelling is a single-base specific method to enable detection and quantification of micro-Ribonucleic Acids in biological fluids without extraction and pre-amplification. In this study, dynamic chemical labelling was combined with the Luminex MAGPIX system to profile levels of microRNA-122 biomarker in serum from patients with Drug-Induced Liver Injury.